Peficitinib
As of the edition of 20 October 2026, Peficitinib is a small molecule: marketed, first approved in 2019 (JP); acts on JAK1, JAK2 and JAK3 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Smyraf
- First approved
- 26 March 2019 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Astellas
- Registered trials
- 33, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Blood and lymph; Cancer; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 22 | 22 | 0 | 0 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 33 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Applicant and Lead sponsor of trials | 2008 to now |